| Bioactivity | SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD)[1]. |
| Invitro | SB 706504 (3 μM, 6 h)可显着降低 IL-1β、IL-6、GM-CSF、TNFα 和 IL-8 mRNA 水平,在 LPS 刺激的 单核细胞来源的巨噬细胞 (MDM)中[1]。SB 706504(3 μM, 6 h)可显着降低 COPD 患者肺泡巨噬细胞(AM)中 LPS 诱导的 TNFα 水平,抑制率为 67.4%[1]。 |
| Name | SB 706504 |
| CAS | 911110-38-8 |
| Formula | C24H19F3N8O |
| Molar Mass | 492.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lauren M. Kent, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). |